The short answer
Two registered tirzepatide trials cover younger populations. NCT06075667 is a Phase 3 in 160 adolescents aged 12 to 17 with a BMI primary endpoint. NCT05696847 is a completed Phase 1 in 28 children aged 6 to 11 whose primary outcome is adverse events.
Key facts
- NCT06075667
- Phase 3, n=160, ages 12-17
- Its status
- Active, not recruiting
- Its primary outcome
- Percent change from baseline in BMI
- Primary completion
- 2 June 2026
- NCT05696847
- Phase 1, n=28, ages 6-11
- Its status
- Completed
- Its primary outcome
- Treatment-emergent and serious adverse events
- Sponsor
- Eli Lilly and Company
Why the phase distinction is not pedantry
A Phase 3 in 160 adolescents is designed to establish whether the compound works and is powered for an efficacy endpoint. A Phase 1 in 28 children is designed to characterise safety and tolerability, with adverse events as the primary outcome. Reporting the second as a dedicated paediatric obesity trial with results pending sets an expectation the study was never built to meet.
The age split is deliberate
One trial covers 12 to 17, the other 6 to 11. Those are different populations physiologically, not merely different numbers. Puberty falls between them, and it changes body composition, growth velocity and hormonal context substantially. Regulators generally require separate evidence for separate age bands for this reason.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the Phase 3 measures
Percent change from baseline in body mass index, per the registry. Not body weight. That follows directly from the participants still growing, and it means the eventual headline number will not be comparable with adult tirzepatide figures however similarly it is reported.
The naming problem, again
NCT06075667 is referred to in coverage under a programme acronym that the registry does not carry; its acronym field is empty. This is the second time on this site that a trial widely discussed by name has turned out to have no registered acronym, the other being the CagriSema head-to-head. Searching a programme name can return nothing while the trial exists.
Where the timeline actually sits
The registry records primary completion for NCT06075667 as 2 June 2026, with the study active and not recruiting. Primary completion means the last participant has reached the primary endpoint assessment, so data exists; publication follows separately and is not automatic or immediate.
The boundary that applies throughout
Tirzepatide is a licensed medicine for adults and is not authorised for paediatric obesity. These are registered trials under clinical supervision with ethics approval. Nothing supplied on this site is tirzepatide, relates to it, or is appropriate for a child in any circumstance.
Quick reference
| NCT06075667 | NCT05696847 | |
|---|---|---|
| Phase | 3 | 1 |
| Enrolment | 160 | 28 |
| Ages | 12-17 | 6-11 |
| Primary outcome | % change in BMI | Adverse events |
| Status | Active, not recruiting | Completed |
Frequently asked questions
Is tirzepatide approved for children?
No. It is not authorised for paediatric obesity. Both studies described are registered clinical trials.
Why are there separate trials for different ages?
Puberty falls between the two age bands and changes body composition, growth velocity and hormonal context substantially.
Is the Phase 1 study an efficacy trial?
No. Its primary outcome is treatment-emergent and serious adverse events. It is a safety and tolerability study in 28 children.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov · Tirzepatide once weekly in adolescent participants with obesity or overweight (NCT06075667)clinicaltrials.gov
- TrialClinicalTrials.gov · Tirzepatide in pediatric participants with obesity (NCT05696847)clinicaltrials.gov
- PubMedWeghuber D et al., Once-Weekly Semaglutide in Adolescents with Obesity. NEJM 2022 (PMID 36322838)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- When Low Muscle and High Fat Occur TogetherA 2026 paper describes sarcopenic obesity in children using clinical data and a juvenile mouse model. Why the body composition question is sharper in the young.
- Slowing the Stomach Changes When a Tablet ArrivesMost oral drugs are absorbed in the small intestine, so gastric emptying controls when absorption starts. Slowing it flattens the concentration peak.
- One Compound, Not the Whole ClassTirzepatide reduced peak contraceptive hormone concentrations by 55-66% in reported data. Semaglutide, liraglutide and dulaglutide did not show the effect.
- Where the Thyroid Warning Came FromRodents given GLP-1 agonists developed C-cell hyperplasia and tumours. The 2010 paper that established it, and why it was an on-target effect.
- Normal Human Thyroid Has No Detectable GLP-1 ReceptorsWaser 2011 measured incretin receptors in rodent and human thyroid. The species difference is stark - and the human receptor picture points at GIP, not GLP-1.